Skip to main content
Erschienen in: Pediatric Nephrology 8/2003

01.08.2003 | Original Article

Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS

verfasst von: Mouin G. Seikaly, P. L. Ho, Lea Emmett, Richard N. Fine, Amir Tejani

Erschienen in: Pediatric Nephrology | Ausgabe 8/2003

Einloggen, um Zugang zu erhalten

Abstract

End-stage renal disease (ESRD) is a major cause of morbidity in children. Besides its high cost to society, ESRD carries significant mortality. Chronic renal insufficiency (CRI) often precedes ESRD. Identifying factors that correlate with the rate of progression to ESRD is beneficial in the management of children with CRI. Since 1994 the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) has extended its registry to include children with CRI, defined as creatinine clearance (C Cr) <75 ml/min per 1.73 m2. As of January 2001, our database registered 4,666 children (<20 years of age) with CRI. Data analysis showed that at least 40% of patients entered had congenital urological anomalies; 39% of patients were followed for at least 3 years. Follow-up data showed that 31% of all registered patients progressed to ESRD by the end of the reporting period. There was a correlation between CRI and several co-morbid clinical factors: low hematocrit, hypoalbuminemia, hypocalcemia, hyperphosphatemia, and hyperparathyroidism, and the rate of progression to ESRD. Primary clinical diagnosis and the age at entry into registry were additional factors that correlated with the rate of progression to ESRD. The main cause of hospitalization in this registry was infection, which accounted for 45% of hospital admissions. Growth delay measured by standard deviation score at baseline was –1.40 at the time of registration. Our data suggest potential areas of improved care that could impact the onset of ESRD.
Literatur
1.
Zurück zum Zitat Obrador GT, Pereira BJG (1998) Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis 31:398–417PubMed Obrador GT, Pereira BJG (1998) Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis 31:398–417PubMed
2.
Zurück zum Zitat Obrador GT, Arora P, Kausz AT, Pereira BJG (1998) Pre-end-stage renal disease care in the United States: a state of disrepair. J Am Soc Nephrol 9 [Suppl]:S44-S54 Obrador GT, Arora P, Kausz AT, Pereira BJG (1998) Pre-end-stage renal disease care in the United States: a state of disrepair. J Am Soc Nephrol 9 [Suppl]:S44-S54
3.
Zurück zum Zitat Mitch WE (1991) Dietary protein restriction in patients with chronic renal failure. Kidney Int 29:734 Mitch WE (1991) Dietary protein restriction in patients with chronic renal failure. Kidney Int 29:734
4.
Zurück zum Zitat Port FK (1994) Morbidity and mortality in dialysis patients. Kidney Int46:1728–1737 Port FK (1994) Morbidity and mortality in dialysis patients. Kidney Int46:1728–1737
5.
Zurück zum Zitat Malangone JM, Abuelo JG, Pezzullo JC, Lund K, McGloin CA (1989) Clinical and laboratory features of patients with chronic renal disease at the start of dialysis. Clin Nephrol 31:77–87PubMed Malangone JM, Abuelo JG, Pezzullo JC, Lund K, McGloin CA (1989) Clinical and laboratory features of patients with chronic renal disease at the start of dialysis. Clin Nephrol 31:77–87PubMed
6.
Zurück zum Zitat Ismail N (1997) Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients. Semin Nephrol 17:270PubMed Ismail N (1997) Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients. Semin Nephrol 17:270PubMed
7.
Zurück zum Zitat Levin A (1999) Anaemia in the patient with renal insufficiency: documenting the impact and reviewing treatment strategies. Nephrol Dial Transplant 14:292–295CrossRefPubMed Levin A (1999) Anaemia in the patient with renal insufficiency: documenting the impact and reviewing treatment strategies. Nephrol Dial Transplant 14:292–295CrossRefPubMed
8.
Zurück zum Zitat Jungers P (1999) Screening for renal insufficiency: is it worthwhile? Is it feasible? Nephrol Dial Transplant 14:2082–2084 Jungers P (1999) Screening for renal insufficiency: is it worthwhile? Is it feasible? Nephrol Dial Transplant 14:2082–2084
9.
Zurück zum Zitat Nissenson AR, Collins AJ, Hurley J, Peterson H, Pereira BJG, Steinbery EP (2001) Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 12:1713–1720PubMed Nissenson AR, Collins AJ, Hurley J, Peterson H, Pereira BJG, Steinbery EP (2001) Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 12:1713–1720PubMed
10.
Zurück zum Zitat Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMed Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMed
11.
Zurück zum Zitat Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed
12.
Zurück zum Zitat Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A (1997) Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541–548PubMed Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A (1997) Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541–548PubMed
13.
Zurück zum Zitat Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D (1999) Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214–2219CrossRefPubMed Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D (1999) Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214–2219CrossRefPubMed
14.
Zurück zum Zitat Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M (2000) Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250–256PubMed Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M (2000) Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250–256PubMed
15.
Zurück zum Zitat USRDS (1997) Annual Data Report. National Institutes of Health, Bethesda, Md. USRDS (1997) Annual Data Report. National Institutes of Health, Bethesda, Md.
16.
Zurück zum Zitat Schmidt RJ, Domico JR, Sorkin MI, Hobbs G (1998) Early referral and its impact on emergent first dialyses, health care costs, and outcomes. Am J Kidney Dis 32:278–283PubMed Schmidt RJ, Domico JR, Sorkin MI, Hobbs G (1998) Early referral and its impact on emergent first dialyses, health care costs, and outcomes. Am J Kidney Dis 32:278–283PubMed
17.
Zurück zum Zitat Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA (1999) Delayed referral of black, Hispanic, and older patients with chronic renal failure. Am J Kidney Dis 33:728–733PubMed Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA (1999) Delayed referral of black, Hispanic, and older patients with chronic renal failure. Am J Kidney Dis 33:728–733PubMed
18.
Zurück zum Zitat Khan IH, Catto GRD, Edward N, MacLeod AM (1994) Chronic renal failure: factors influencing nephrology referral. QJM 87:559–564PubMed Khan IH, Catto GRD, Edward N, MacLeod AM (1994) Chronic renal failure: factors influencing nephrology referral. QJM 87:559–564PubMed
19.
Zurück zum Zitat Campbell JD, Ewigman B, Hosokawa M, Van Stone JC (1989) The timing of referral of patients with end-stage renal disease. Nephrol Dial Transplant 18:660 Campbell JD, Ewigman B, Hosokawa M, Van Stone JC (1989) The timing of referral of patients with end-stage renal disease. Nephrol Dial Transplant 18:660
20.
Zurück zum Zitat Chan JCM, Goplerud JM, Papadopoulou ZL, Novello AC (1981) Kidney failure in childhood. Int J Pediatr Nephrol 2:201 Chan JCM, Goplerud JM, Papadopoulou ZL, Novello AC (1981) Kidney failure in childhood. Int J Pediatr Nephrol 2:201
21.
Zurück zum Zitat Portale AA, Booth BE, Halloran BP, Morris RC (1984) Effect of dietary phosphorus on circulating concentrations of 1,25-dihydrocholecalciferol and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580–1589PubMed Portale AA, Booth BE, Halloran BP, Morris RC (1984) Effect of dietary phosphorus on circulating concentrations of 1,25-dihydrocholecalciferol and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580–1589PubMed
22.
Zurück zum Zitat Sanchez CP, Goodman W, Salusky IB (1999) Osteodystrophy. In: Barratt T, Avner E, Harmon W (eds) Pediatric nephrology, 4th edn. Lippincott Williams and Wilkins, Baltimore, p 1231 Sanchez CP, Goodman W, Salusky IB (1999) Osteodystrophy. In: Barratt T, Avner E, Harmon W (eds) Pediatric nephrology, 4th edn. Lippincott Williams and Wilkins, Baltimore, p 1231
23.
Zurück zum Zitat Malluche HH, Ritz E, Lange HP, et. al (1976) Bone histology in incipient and advanced renal failure. Kidney Int 9:355–362PubMed Malluche HH, Ritz E, Lange HP, et. al (1976) Bone histology in incipient and advanced renal failure. Kidney Int 9:355–362PubMed
24.
Zurück zum Zitat Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL (1970) The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest49:2146–2149 Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL (1970) The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest49:2146–2149
25.
Zurück zum Zitat Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296–1301PubMed Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296–1301PubMed
26.
Zurück zum Zitat Lieberman KV, Tejani A (1996) A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56–63PubMed Lieberman KV, Tejani A (1996) A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56–63PubMed
27.
Zurück zum Zitat Montini G, Zacchello G, Baraldi E, Zanconato S, Fabris F, Andreetta B, Pavanello L, Zacchello F (1990) Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 117:556–560PubMed Montini G, Zacchello G, Baraldi E, Zanconato S, Fabris F, Andreetta B, Pavanello L, Zacchello F (1990) Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 117:556–560PubMed
28.
Zurück zum Zitat Fabris F, Cordiano I, Randi ML, Casonato A, Montini G, Zacchello G, Girolami A (1991) Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by hemodialysis. Pediatr Nephrol 5:225–228PubMed Fabris F, Cordiano I, Randi ML, Casonato A, Montini G, Zacchello G, Girolami A (1991) Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by hemodialysis. Pediatr Nephrol 5:225–228PubMed
29.
Zurück zum Zitat Rigden SP, Montini G, Morris M, Keneth K, Haycock GB, Chantler C, Hill RC (1990) Recombinant human erythropoietin therapy in children maintained by hemodialysis. Pediatr Nephrol 4:618–622PubMed Rigden SP, Montini G, Morris M, Keneth K, Haycock GB, Chantler C, Hill RC (1990) Recombinant human erythropoietin therapy in children maintained by hemodialysis. Pediatr Nephrol 4:618–622PubMed
30.
Zurück zum Zitat Campos A, Garin EH (1992) Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO). Clin Pediatr (Phila) 31:94 Campos A, Garin EH (1992) Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO). Clin Pediatr (Phila) 31:94
31.
Zurück zum Zitat Anonymous (1997) NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30 [Suppl 3]:S194 Anonymous (1997) NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30 [Suppl 3]:S194
32.
Zurück zum Zitat Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB (1989) Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38:12–18 Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB (1989) Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38:12–18
33.
Zurück zum Zitat Lundin AP (1989) Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 9:22PubMed Lundin AP (1989) Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 9:22PubMed
34.
Zurück zum Zitat Jabs K, Harmon WE (1996) Recombinant human erythropoietin therapy in children on dialysis. Adv Ren Replace Ther 3:24–36PubMed Jabs K, Harmon WE (1996) Recombinant human erythropoietin therapy in children on dialysis. Adv Ren Replace Ther 3:24–36PubMed
35.
Zurück zum Zitat Burke JR, on behalf of the Australian and New Zealand Paediatric Nephrology Association (1995) Low-dose subcutaneous erythropoietin in children with chronic renal failure. Pediatr Nephrol 9:558–561PubMed Burke JR, on behalf of the Australian and New Zealand Paediatric Nephrology Association (1995) Low-dose subcutaneous erythropoietin in children with chronic renal failure. Pediatr Nephrol 9:558–561PubMed
36.
Zurück zum Zitat Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMed Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMed
37.
Zurück zum Zitat Massry SG, Smogorzewski M (1994) Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219–231PubMed Massry SG, Smogorzewski M (1994) Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219–231PubMed
38.
Zurück zum Zitat Scwelder S, Schnizel R, Vaith P, Wanner C (2001) Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 59:S32–S36 Scwelder S, Schnizel R, Vaith P, Wanner C (2001) Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 59:S32–S36
39.
Zurück zum Zitat Deuther-Conrad W, Franke S, Sommer M, Henle T, Sein G (2001) Differences in the modulating potential of advanced glycation end products (AGE) peptides versus AGE proteins. Kidney Int 59:S63–S66 Deuther-Conrad W, Franke S, Sommer M, Henle T, Sein G (2001) Differences in the modulating potential of advanced glycation end products (AGE) peptides versus AGE proteins. Kidney Int 59:S63–S66
40.
Zurück zum Zitat Pennell JP (2001) Optimizing medical management of patients with pre-end-stage renal disease: Am J Med 111:559–568 Pennell JP (2001) Optimizing medical management of patients with pre-end-stage renal disease: Am J Med 111:559–568
41.
Zurück zum Zitat Bergstrom J, Lindholm B (1998) Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis. 32:834–841 Bergstrom J, Lindholm B (1998) Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis. 32:834–841
42.
Zurück zum Zitat Tenvinkel P, Heimburgger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1991) Strong association between malnutrition, inflammation, and atherosclerosis in renal failure. Kidney Int 55:1899–1911CrossRef Tenvinkel P, Heimburgger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1991) Strong association between malnutrition, inflammation, and atherosclerosis in renal failure. Kidney Int 55:1899–1911CrossRef
43.
Zurück zum Zitat Tönshoff B, Schaefer F, Mehls O (1990) Disturbance of growth hormone-insulin-like growth factor axis in uremia. Pediatr Nephrol 4:654–662 Tönshoff B, Schaefer F, Mehls O (1990) Disturbance of growth hormone-insulin-like growth factor axis in uremia. Pediatr Nephrol 4:654–662
44.
Zurück zum Zitat Fine RN, Kohaut E, Brown D, Perlman AJ, for the Genentech Collaborative Study Group (1994) Growth after recombinant human growth hormone in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr 124:374–382PubMed Fine RN, Kohaut E, Brown D, Perlman AJ, for the Genentech Collaborative Study Group (1994) Growth after recombinant human growth hormone in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr 124:374–382PubMed
Metadaten
Titel
Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS
verfasst von
Mouin G. Seikaly
P. L. Ho
Lea Emmett
Richard N. Fine
Amir Tejani
Publikationsdatum
01.08.2003
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 8/2003
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-003-1158-5

Weitere Artikel der Ausgabe 8/2003

Pediatric Nephrology 8/2003 Zur Ausgabe

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.